Overview
Fidaxomicin is an antibacterial drug that acts locally in the gastrointestinal tract on C. difficile. It is a fermentation product obtained from the Actinomycete Dactylosporangium aurantiacum. Fidaxomicin is a macrolide antibacterial drug that inhibits RNA synthesis by binding to RNA polymerases.

Coverage Guidelines
Authorization may be granted for members when ALL the following criteria are met, and documentation is provided:

1. The member is diagnosed with Clostridioides (formerly Clostridium) difficile infection confirmed by a positive stool assay
2. The member meets ONE of the following:
   a. The patient requires additional medication to complete a 10-day course of the requested drug for therapy that was initiated in the hospital
   b. The patient has experienced an inadequate treatment response to oral vancomycin after a trial of at least 7 days, OR has intolerance or contraindication to vancomycin

Limitations
1. Initial approvals will be granted for 10 days.
2. The following quantity limits apply:
   - Dificid 200mg oral tablet: 20 tablets per 10 days
   - Dificid 40mg/mL oral suspension: 136mL per 10 days
References

Review History
07/21/2021- Reviewed July P&T; changed diagnosis name; removed “diarrhea-associated” and added “infection. Effective 10/01/2021.

Disclaimer
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.